When the job you were hired for changes: Realigning job descriptions with job priorities

In this poster, two librarians at two different institutions will present results of job audits they completed, based on the Academic Library Value: The Impact Starter Kit by Megan Oakleaf (2017). Collaborating across institutions, these early-career librarians were able to work through the job audit process together, and engage in open discussions that might have been impossible with a different colleague at their home institutions. These librarians each decided to complete a job audit because they saw a need to recast their job descriptions. Each holds a position that was newly created at the time they were hired, in order to support their colleges’ rapid growth in online, distance, and hybrid education. At the same time, these librarians were new to librarianship, and faced similar challenges. First of these challenges was learning a new job in an environment where each librarian knew their position was needed, but there were no signposts. As they settled into their roles, and continued to grow their work, they began to realize that much of their jobs had morphed due to change in both of their home institutions. Their job descriptions no longer accurately represented their actual day-to-day work, and they started looking for a way to reconcile this disparity. Poster attendees will not only see the results of these two job audits, but have the chance to hear from these librarians about their experiences. Attendees will learn about changes have made at their respective institutions regarding their job descriptions. Poster attendees will be able to understand the job audit process in order to be able to do it themselves. This poster will provide a starting point for conversations about realigning job priorities to your institution, proving your value, and reinvigorating the love you have for your job

Building women leaders: Recasting early career leadership

Are you a new librarian facing leadership challenges? Do you identify as a woman? Are you wondering how you can lead with no official authority? Most library workers across the U.S. are women, yet women librarians still face structural and institutional barriers to leading. Join a discussion about women librarians and the obstacles they face while learning how to be a leader. Learn from other early-career, women librarians who have been working to build their leadership capacity. We invite women from a variety of contexts, backgrounds, and identities to take part in this conversation

Fresh Perspectives From the Field: The Voices of New Distance Librarians

Sometimes the newest voices are the ones we want to hear. New librarians start their first library jobs with valuable original ideas—but how do we listen to them and bring their voices into the conversation? Panelists will share their experiences as new librarians, in newly created Distance Librarian positions. Come share your voice, and ask us questions about our challenges, success, and failures. Don’t just listen to new librarians talk. Come with your ideas, so we can discuss how new and experienced librarians can build a community. This is a session for both new and experienced librarians

How to Get an Embedded Librarian Job

Webinar presented by the Special Libraries Association Embedded Librarians Caucus on December 15, 2015. Webinar video link: https://bit.ly/2YB6Dz4 How come there are never any “Embedded Librarian” job ads? What are embedded librarian jobs? Where can you find them? What are their requirements? And most important, how do I get one? For this webinar, five members of the Embedded Librarians Caucus answered these questions, shared how they found their embedded librarian jobs, and more. Panel Moderator: David Shumaker. Panelists: * Nadine Anderson, Behavioral Sciences Librarian, University of Michigan-Dearborn * Rachel Altman, Corporate Research Analyst, Grant Thornton International, Ltd. * Mia Breitkopf, Online and Hybrid Learning Librarian, The College at Brockport, State University of New York * Jamie Marie Keller-Aschenbach, Head of Research and Access Services, Florida Coastal School of Law * George Peckham-Rooney, Data and Operations Specialist, Seyfarth ShawWebinar presented by the Special Libraries Association Embedded Librarians Caucus on December 15, 2015. Webinar video link: https://bit.ly/2YB6Dz4https://deepblue.lib.umich.edu/bitstream/2027.42/150199/1/How to Get An Embedded Librarian Job.pdfDescription of How to Get An Embedded Librarian Job.pdf : Presentation Slide

(13:50) Banned Books and the Library

Presented at the Maus Symposium on April 5, 2022, at St. John Fisher College.https://fisherpub.sjfc.edu/maus-symposium-2022/1010/thumbnail.jp

(13:50) Banned Books and the Library

Presented at the Maus Symposium on April 5, 2022, at St. John Fisher College.https://fisherpub.sjf.edu/maus-symposium-2022/1010/thumbnail.jp

Project management techniques to finally finish a LibGuides update

St. John Fisher University is the home of Lavery Library, the only library on the campus of a small doctoral-granting institution in Rochester, New York. Over the past couple of years, the three authors have formed a coalition for updating LibGuides in a participatory way. During the summer of 2022, we led a project to reorganize our library’s LibGuides homepage, the index of our guides. Learn how we used project management techniques to complete this task

Efficacy and safety of baricitinib in hospitalized adults with severe or critical COVID-19 (Bari-SolidAct): a randomised, double-blind, placebo-controlled phase 3 trial

International audienceAbstract Background Baricitinib has shown efficacy in hospitalized patients with COVID-19, but no placebo-controlled trials have focused specifically on severe/critical COVID, including vaccinated participants. Methods Bari-SolidAct is a phase-3, multicentre, randomised, double-blind, placebo-controlled trial, enrolling participants from June 3, 2021 to March 7, 2022, stopped prematurely for external evidence. Patients with severe/critical COVID-19 were randomised to Baricitinib 4 mg once daily or placebo, added to standard of care. The primary endpoint was all-cause mortality within 60 days. Participants were remotely followed to day 90 for safety and patient related outcome measures. Results Two hundred ninety-nine patients were screened, 284 randomised, and 275 received study drug or placebo and were included in the modified intent-to-treat analyses (139 receiving baricitinib and 136 placebo). Median age was 60 (IQR 49–69) years, 77% were male and 35% had received at least one dose of SARS-CoV2 vaccine. There were 21 deaths at day 60 in each group, 15.1% in the baricitinib group and 15.4% in the placebo group (adjusted absolute difference and 95% CI − 0.1% [− 8·3 to 8·0]). In sensitivity analysis censoring observations after drug discontinuation or rescue therapy (tocilizumab/increased steroid dose), proportions of death were 5.8% versus 8.8% (− 3.2% [− 9.0 to 2.7]), respectively. There were 148 serious adverse events in 46 participants (33.1%) receiving baricitinib and 155 in 51 participants (37.5%) receiving placebo. In subgroup analyses, there was a potential interaction between vaccination status and treatment allocation on 60-day mortality. In a subsequent post hoc analysis there was a significant interaction between vaccination status and treatment allocation on the occurrence of serious adverse events, with more respiratory complications and severe infections in vaccinated participants treated with baricitinib. Vaccinated participants were on average 11 years older, with more comorbidities. Conclusion This clinical trial was prematurely stopped for external evidence and therefore underpowered to conclude on a potential survival benefit of baricitinib in severe/critical COVID-19. We observed a possible safety signal in vaccinated participants, who were older with more comorbidities. Although based on a post-hoc analysis, these findings warrant further investigation in other trials and real-world studies. Trial registration Bari-SolidAct is registered at NCT04891133 (registered May 18, 2021) and EUClinicalTrials.eu ( 2022-500385-99-00 )